Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 1
1969 2
1970 4
1971 2
1972 5
1974 1
1975 2
1976 2
1978 2
1979 1
1980 1
1983 2
1984 3
1985 2
1986 9
1987 6
1988 2
1989 2
1990 5
1991 7
1992 1
1993 4
1994 5
1995 3
1996 5
1997 8
1998 4
1999 4
2000 2
2001 1
2002 4
2003 11
2004 6
2005 17
2006 8
2007 7
2008 10
2009 12
2010 14
2011 20
2012 14
2013 14
2014 18
2015 15
2016 15
2017 20
2018 18
2019 22
2020 23
2021 15
2022 14
2023 6
2024 10
2025 10
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
HER2-Positive Breast Cancer Treatment and Resistance.
Veeraraghavan J, De Angelis C, Gutierrez C, Liao FT, Sabotta C, Rimawi MF, Osborne CK, Schiff R. Veeraraghavan J, et al. Among authors: schiff r. Adv Exp Med Biol. 2025;1464:495-525. doi: 10.1007/978-3-031-70875-6_24. Adv Exp Med Biol. 2025. PMID: 39821040 Review.
Metacognitive Strategies.
Schiff R, Nuri Ben-Shushan Y, Ben-Artzi E. Schiff R, et al. J Learn Disabil. 2017 Mar/Apr;50(2):143-157. doi: 10.1177/0022219415589847. Epub 2016 Aug 4. J Learn Disabil. 2017. PMID: 26054726
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, Ma W, De Angelis C, Morlando A, O'Donnell M, Naumenko S, Huang S, Nguyen QD, Huang Y, Malorni L, Bergholz JS, Zhao JJ, Fraenkel E, Lim E, Schiff R, Shapiro GI, Jeselsohn R. Guarducci C, et al. Among authors: schiff r. Clin Cancer Res. 2024 May 1;30(9):1889-1905. doi: 10.1158/1078-0432.CCR-23-2975. Clin Cancer Res. 2024. PMID: 38381406 Free PMC article.
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, Schiff R, Jiang B, Jovanovic B, Nowak K, Ericsson M, Cameron M, Gray N, Dillon D, Zhao JJ, Sabatini DM, Jeselsohn R, Brown M, Polyak K, Sicinski P. Fassl A, et al. Among authors: schiff r. Sci Adv. 2020 Jun 17;6(25):eabb2210. doi: 10.1126/sciadv.abb2210. eCollection 2020 Jun. Sci Adv. 2020. PMID: 32704543 Free PMC article.
Elacestrant and the Promise of Oral SERDs.
Sanchez KG, Nangia JR, Schiff R, Rimawi MF. Sanchez KG, et al. Among authors: schiff r. J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841. Epub 2022 Jun 23. J Clin Oncol. 2022. PMID: 35737918 No abstract available.
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Winer EP, Fu X, Schiff R, Long HW, Metzger Filho O, Jeselsohn R. Nardone A, et al. Among authors: schiff r. Cancer Res. 2022 Oct 17;82(20):3673-3686. doi: 10.1158/0008-5472.CAN-21-3186. Cancer Res. 2022. PMID: 35950920 Free PMC article.
Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.
Cleland JGF, Pellicori P, Graham FJ, Lane R, Petrie MC, Ahmed F, Squire IB, Ludman A, Japp A, Al-Mohammad A, Clark AL, Szwejkowski B, Critoph C, Chong V, Schiff R, Nageh T, Glover J, McMurray JJV, Thomson EA, Robertson M, Ford I, Kalra PA, Kalra PR; IRONMAN Study Group. Cleland JGF, et al. Among authors: schiff r. J Am Coll Cardiol. 2024 Oct 29;84(18):1704-1717. doi: 10.1016/j.jacc.2024.08.052. J Am Coll Cardiol. 2024. PMID: 39443013 Free PMC article. Clinical Trial.
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.
Maurer C, Agostinetto E, Ameye L, Lambertini M, Martel S, Ponde N, Brandão M, Poggio F, Ferreira A, Schiff R, De Angelis C, Gelber RD, Dent S, Thomssen C, Piccart M, de Azambuja E. Maurer C, et al. Among authors: schiff r. Breast Cancer Res Treat. 2025 Jul;212(1):57-69. doi: 10.1007/s10549-025-07699-2. Epub 2025 Apr 28. Breast Cancer Res Treat. 2025. PMID: 40293644 Free PMC article. Clinical Trial.
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.
Parsons HA, Messer C, Santos K, Weiss J, Merrell D, Danysh BP, Hughes ME, Kirkner GJ, Patel A, Hess J, Sendrick K, Stewart C, Grant E, Schlueter-Kuck K, Grinshpun A, Wagle N, Veeraraghavan J, Leone JP, Freedman RA, Metzger O, Schiff R, Winer EP, Tolaney SM, Rimawi M, Krop IE, Getz G, Lin NU. Parsons HA, et al. Among authors: schiff r. Cell Genom. 2025 Dec 10;5(12):100987. doi: 10.1016/j.xgen.2025.100987. Epub 2025 Sep 9. Cell Genom. 2025. PMID: 40930104 Free PMC article.
378 results